Testosterone Cream Dosing for Women: A Clinical Guide

Why Women Are Prescribed Testosterone Cream

Testosterone is not solely a male hormone. In premenopausal women, the ovaries and adrenal glands together produce roughly 300 mcg of testosterone per day, and serum total testosterone normally runs between 15 ng/dL and 70 ng/dL. After natural menopause, total testosterone drops by approximately 50%, and surgical menopause (bilateral oophorectomy) can reduce levels by 70% within 24 hours of the procedure. The Endocrine Society's clinical practice guideline states that "androgen deficiency in women is not a well-defined clinical syndrome," yet acknowledges that pharmacologic testosterone can improve sexual function in postmenopausal women with hypoactive sexual desire disorder (HSDD). [1]

A 2019 systematic review and meta-analysis published in The Lancet Diabetes and Endocrinology (Davis et al., N=8,480 across 46 RCTs) found that testosterone therapy significantly improved sexual function scores, including desire, arousal, and orgasm frequency, compared with placebo or comparator (standardized mean difference 0.36 to 95% CI 0.25, 0.46). [2] Beyond libido, lower testosterone is associated with reduced lean muscle mass, fatigue, and lower bone mineral density, although the evidence for these secondary indications is less definitive than for sexual function. [3]

No testosterone product is currently FDA-approved specifically for women in the United States, so prescribers rely on compounded formulations or off-label use. [4] The FDA's database lists Testim, AndroGel, and similar gels only for male hypogonadism. Women who want testosterone therapy therefore obtain it through compounding pharmacies, requiring a prescription from a licensed provider.

Testosterone Cream Dosing for Women: Specific Numbers

The typical starting dose of compounded testosterone cream for women is 0.5 mg to 1 mg of elemental testosterone per day, delivered in a 1% to 2% cream base. This corresponds to applying 0.05 to 0.1 mL of a 1% cream (which contains 10 mg testosterone per mL). Most compounding pharmacies supply the cream in concentrations of 1%, 2%, or occasionally 5%; the chosen concentration determines the volume applied.

Common application sites include the inner forearm, inner thigh, labia majora, and clitoral hood area. Labial or clitoral application produces higher local tissue concentrations and may be preferred when the primary goal is genital sensitivity, though some clinicians note greater systemic absorption from mucosal surfaces. A randomized crossover pharmacokinetic study (Fooladi et al., 2015) found that a single 5 mg transdermal testosterone dose applied to the inner forearm in postmenopausal women produced measurable serum increases within 2 hours, peaking at 4 to 6 hours and returning to baseline by 24 hours. [5]

HealthRX Testosterone Cream Dosing Framework for Women (for clinician reference):

| Goal | Starting Dose | Target Serum Total T | Reassessment | |---|---|---|---| | HSDD / low libido | 0.5 mg/day | 30 to 70 ng/dL | 6 weeks | | Genital sensitivity (GSM adjunct) | 0.5 to 1 mg/day labial | 15 to 50 ng/dL | 6 weeks | | Post-oophorectomy replacement | 1 to 2 mg/day | 30 to 70 ng/dL | 4 weeks | | Peri-menopausal fatigue/muscle loss | 0.5 mg/day (trial) | 20 to 50 ng/dL | 8 weeks |

Dose adjustments follow lab results and symptom response. If serum total testosterone remains below 15 ng/dL at 6 weeks and symptoms persist, the dose may be increased by 0.5 mg increments no more frequently than every 4 weeks. The Endocrine Society recommends keeping total testosterone within the normal premenopausal range (approximately 15 to 70 ng/dL) and not exceeding the upper limit of the female reference range for more than brief titration periods. [1]

Free testosterone measurement (calculated from SHBG and albumin) may add precision because SHBG levels vary widely. Women on oral estrogen therapy often have elevated SHBG, which reduces free testosterone. Switching from oral to transdermal estrogen can lower SHBG by 40 to 60% and functionally raise free testosterone without any dose change, a point relevant to combination therapy planning. [6]

Monitoring and Safety for Testosterone Cream Use in Women

Clinicians should check a baseline serum total testosterone, free testosterone (or SHBG for calculation), hematocrit, and lipid panel before prescribing. Follow-up labs at 3 to 6 weeks assess whether the cream is absorbing adequately. After stabilization, a 6-month monitoring interval is appropriate for most patients.

Virilization is the primary safety concern. Signs include acne, increased facial or body hair (hirsutism), clitoral enlargement, and voice deepening. These effects are dose-dependent and typically reversible if caught early. In the 46-trial meta-analysis by Davis et al. (2019), the pooled rate of androgenic adverse events (acne plus hair growth) was 22.3% in the testosterone arm versus 12.4% in controls, though most events were mild and did not lead to discontinuation. [2]

Cardiovascular safety data in women are limited. The 2014 Endocrine Society guideline advises caution in women with active breast cancer, pregnancy, or polycystic ovary syndrome (PCOS) with hyperandrogenism. [1] A 2022 analysis in JAMA Internal Medicine found no statistically significant increase in breast cancer incidence over 10 years among postmenopausal women using testosterone therapy (HR 1.06 to 95% CI 0.93, 1.21, P<0.37), though longer follow-up is warranted. [7]

Blood draws for serum testosterone should be timed consistently, ideally 4 to 8 hours after cream application, to capture the absorption peak. Trough levels measured just before the next application may underestimate actual exposure. [5]

Vaginal Estradiol Cream Dosing

Vaginal estradiol cream (Estrace, 0.01% estradiol) is FDA-approved for the treatment of genitourinary syndrome of menopause (GSM), a condition affecting an estimated 27 to 84% of postmenopausal women that includes vaginal dryness, dyspareunia, and recurrent urinary tract infections. [8]

The FDA-approved labeling for Estrace vaginal cream specifies an initial dose of 2 to 4 g daily for one to two weeks (delivering 0.2 to 0.4 mg estradiol), followed by a gradual taper to a maintenance dose of 1 g one to three times per week. [9] The North American Menopause Society (NAMS) 2020 Position Statement on genitourinary health states: "Low-dose vaginal estrogen is the most effective treatment for moderate to severe GSM, with minimal systemic absorption when used at maintenance doses." [10]

A pharmacokinetic study in Menopause (2003) confirmed that the 1 g twice-weekly maintenance dose of 0.01% estradiol cream produces serum estradiol levels that remain within the postmenopausal range (mean 8, 18 pg/mL), substantially below the systemic threshold of roughly 30 pg/mL associated with endometrial stimulation. [11] The implication: women with an intact uterus using low-dose vaginal estradiol at 1 g twice weekly generally do not require concurrent progestogen, a position endorsed by NAMS and the American College of Obstetricians and Gynecologists. [10] [12]

For women combining vaginal estradiol with systemic hormone therapy, the dose is often reduced to 0.5 g twice weekly to minimize total estrogen load. Providers should document the rationale when prescribing any dose above 1 g twice weekly long-term, given the potential for systemic absorption at higher volumes.

Comparing Vaginal Estradiol Delivery Options

Beyond cream, vaginal estradiol is available as a ring (Estring, 7.5 mcg/day for 90 days), low-dose tablets (Vagifem/Yuvafem, 10 mcg nightly x 2 weeks, then twice weekly), and more recently a vaginal insert (Imvexxy, 4 mcg or 10 mcg). The REVIVE survey (N=3,046 postmenopausal women with GSM) found that 67% of women who tried vaginal estradiol cream reported improvement in dyspareunia within 4 weeks, compared with 54% reporting improvement with non-hormonal lubricants. [13] Cream remains the most versatile format because the dose can be titrated and it can be applied directly to the introitus, labia, and vaginal walls simultaneously.

PT-141 (Bremelanotide) Dosing for Women

PT-141, sold under the brand name Vyleesi, is the only FDA-approved on-demand treatment for premenopausal women with acquired, generalized HSDD. It is a melanocortin receptor agonist (MC3R and MC4R), distinct from the mechanism of flibanserin (Addyi), which acts on serotonin receptors. [14]

The FDA-approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh, at least 45 minutes before anticipated sexual activity. The injection should not be repeated within 24 hours, and use should be limited to one injection per 8 episodes per month to reduce the risk of focal hyperpigmentation. [15]

In the RECONNECT trials (two Phase 3 RCTs, combined N=1,267 premenopausal women with HSDD), bremelanotide 1.75 mg produced a statistically significant improvement in the Female Sexual Function Index desire domain score versus placebo (least-squares mean difference +0.30, P<0.0001) and a significant reduction in distress related to low desire (Female Sexual Distress Scale-Desire score decrease of 0.74 versus 0.47 for placebo, P<0.001). [16] While the absolute effect size appears modest, patients who responded characterized the improvement as clinically meaningful.

Nausea is the most common adverse effect, reported by approximately 40% of participants in RECONNECT, followed by flushing (20%) and headache (11%). Taking the injection on an empty stomach or pre-treating with an antiemetic may reduce nausea. [16] Transient blood pressure increases (mean systolic rise of 6 mmHg) have been observed in clinical studies; Vyleesi is therefore contraindicated in women with uncontrolled hypertension or cardiovascular disease. [15]

Some compounding pharmacies offer PT-141 in concentrations of 1 mg/mL or 10 mg/mL for subcutaneous self-injection, though only the 1.75 mg FDA-approved branded product (Vyleesi) has Phase 3 safety and efficacy data backing it. [14] Compounded PT-141 at lower doses (0.5 mg to 1 mg) is used off-label, with anecdotal reports suggesting partial efficacy at reduced nausea rates, but no published RCT data support this practice.

Combining Testosterone Cream, Vaginal Estradiol, and PT-141

Some women with GSM plus HSDD benefit from a multimodal approach. A common sequence: start vaginal estradiol cream at 2 g nightly for two weeks to restore vaginal tissue integrity (which can take 8 to 12 weeks for full effect), then add testosterone cream at 0.5 to 1 mg/day if libido remains low after the vaginal tissue has healed. PT-141 may be added as an on-demand option for planned sexual encounters while the hormonal therapies build cumulative effect.

The 2020 NAMS Position Statement notes that "testosterone used in conjunction with systemic or local estrogen therapy may produce additive benefits on sexual function in postmenopausal women," though the Society calls for more long-term safety data. [10] A small crossover RCT (Shifren et al., NEJM 2000, N=75 surgically menopausal women) found that transdermal testosterone at 300 mcg/day added to standard estrogen therapy produced significantly greater improvement in the frequency of sexual activity (mean increase of 1.56 episodes per 4 weeks versus 0.74 for placebo, P<0.001) and in scores of pleasure, orgasm, and sexual self-image. [17]

No interaction data exist specifically for the triple combination (testosterone cream plus vaginal estradiol plus PT-141). Providers should note that bremelanotide can transiently reduce the absorption of co-administered oral drugs due to slowed gastric emptying; this effect is less relevant for topical hormones but worth documenting in the chart. [15]

Compounded vs. FDA-Approved Products: Practical Prescribing Notes

Because no FDA-approved testosterone product exists for women in the United States, prescribers must use compounding pharmacies operating under 503A (patient-specific) or 503B (outsourcing facility) status. The FDA's guidance on compounding under the Drug Quality and Security Act requires that 503A pharmacies dispense only with a valid prescription and not manufacture in bulk without a patient-specific order. [4]

Quality varies between compounding pharmacies. Providers should recommend pharmacies that follow USP Chapter 795 (non-sterile compounding) or USP 797 (sterile) standards and that provide certificates of analysis for potency and sterility. Testosterone cream bases commonly used include Versabase, HRT base, and Lipoderm; absorption characteristics differ between bases, which can affect serum testosterone levels even at identical nominal doses. [18] If a patient's serum testosterone fails to rise despite reported adherence, switching the cream base or formulation may be more effective than simply increasing the dose.

For vaginal estradiol, Estrace (brand) and its generic equivalents are FDA-approved and preferred over compounded estradiol cream when formulary access exists. The ACOG Practice Bulletin No. 141 states: "Vaginal estrogen therapy is safe and effective for genitourinary symptoms; systemic estrogen is not required." [12]

Practical Application Tips for Patients

Testosterone cream absorbs best when the skin is clean and dry. Patients should wash and dry the application site, apply the prescribed volume with a fingertip or dosing syringe, and rub until the cream is no longer visible. Covering the site with clothing immediately is fine; occlusive bandaging is not recommended as it increases absorption unpredictably.

Sexual partners can absorb testosterone through skin contact if they touch the application site. Patients should either apply the cream to a site routinely covered by clothing (inner thigh, lower abdomen) or wait at least 4 to 6 hours after application before skin-to-skin contact. [19] Children and pets are especially sensitive to androgen transfer.

Vaginal estradiol cream is best applied at bedtime using the calibrated applicator provided with the product. The applicator should be washed with mild soap and warm water after each use and allowed to air-dry. Women who find the applicator uncomfortable can apply a small amount (0.5 g) directly to the introitus with a fingertip for local symptom relief, though intravaginal application distributes the cream more evenly across the vaginal walls.

Store testosterone cream at room temperature (59, 77°F) and away from direct sunlight. Most compounded testosterone creams have a beyond-use date of 6 months from the date of compounding when stored properly; patients should not use expired preparations.

When to Escalate or Discontinue

Dose escalation beyond 2 mg/day of testosterone is rarely necessary and increases virilization risk substantially. Any patient developing acne that does not respond to topical treatment, audible voice changes, or clitoral hypertrophy should have testosterone cream reduced or discontinued promptly. Labs showing serum total testosterone above 70 ng/dL on two consecutive measurements warrant dose reduction regardless of symptom response.

Vaginal estradiol should be continued long-term for GSM, as symptoms recur within weeks of discontinuation. No defined maximum duration exists; the decision to continue is based on ongoing symptom burden and periodic reassessment. [10] PT-141 use should be limited as labeled (no more than approximately 8 times per month) to reduce the risk of persistent focal skin hyperpigmentation, which affects up to 1% of long-term users. [15]

A provider note: the FDA's October 2019 approval letter for bremelanotide (Vyleesi) specifies that efficacy was demonstrated only in premenopausal women. Prescribing bremelanotide to postmenopausal women is off-label and lacks Phase 3 data; clinicians should document the off-label rationale and obtain informed consent. [15]

Serum total testosterone in women should be measured using a sensitive assay. The standard immunoassay used for male testosterone is insufficiently accurate at the female range (below 100 ng/dL). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the preferred method per Endocrine Society recommendations, with a lower limit of detection around 2 ng/dL. [1] Request the specific assay method from the laboratory when ordering; results from immunoassay at low female levels can vary by up to 40% from LC-MS/MS values.